ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomized controlled trials - Part 1 of 9

Thursday, August 20, 2015

Submitted by

Source

Source Name: The Lancet Oncology

Author(s)

Joe Y Chang, Suresh Senan, Marinus A Paul, Reza J Mehran, Alexander V Louie, Peter Balter, Harry J M Groen, Stephen E McRae, Joachim Widder, Lei Feng, Ben E E M van den Borne, Mark F Munsell, Coen Hurkmans, Donald A Berry, Erik van Werkoven, John J Kresl, Anne-Marie Dingemans, Omar Dawood, Cornelius J A Haasbeek, Larry S Carpenter, Katrien De Jaeger, Ritsuko Komaki, Ben J Slotman, Egbert F Smit, Jack A Roth

Thus far, only 3 randomized controlled trials (RCTs) have compared stereotactive ablative radiotherapy (SABR) versus surgery in patients with early stage NSCLC (STARS trial, ROSEL trial, and ACOSOG Z4099 trial). Unfortunately all 3 were unable to meet the accrual goals and were closed early. The current study is a pooled analysis of patients in the STARS trial and ROSEL trial (n=31 in SABR group and n=27 in surgery group). All patients had clinical stage I NSCLC (<4 cm) and were surgical candidates for lobectomy with a performance status of 0 to 2. Of note, patients in the STARS trial required histologic confirmation of NSCLC prior to randomization, but patients in the ROSEL trial did not. Overall 1 and 3-year survival was 100% and 95% in the SABR group and 88% and 79% in the surgery group. There was no significant difference in local, regional, or distant metastases or recurrence-free survival between the two groups. In terms of complications, in the SABR group, 3 (10%) patients had treatment related grade 3 adverse events. In the surgery group, one patient died of complications and 12 (44%) had postoperative grade 3-4 adverse events. The authors concluded that SABR is better tolerated and may lead to improved survival over surgery in patients with stage I NSCLC.

 

Comments

Very interested findings that if repeated by other investigators then it will have serious impact on the management of early stage lung cancer

Add comment

Log in or register to post comments